Transcription profiling of human T-cell lymphoblastic leukemia, acute mylelogenous leukemia and Diffuse Large Cell Lymphoma cell lines after treatment with aplidin and/or cytarabine

ABSTRACT: Aplidin (plitidepsin) is a novel antitumor agent isolated from the Mediterranean tunicate Aplidium albicans. Aplidin has shown impressive in vitro and in vivo activity against various cancer cell lines. Based on the results from several laboratories Aplidin has recently been granted orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL) and Multiple Myeloma (MM) by the European Commision and Food and Drug Administration. Aplidin has selective cytotoxicity in vitro towards leukemia cells as compared to hematopoeitic progenitors and lacks cross-resistance with other known cytotoxic drugs with the exception of gemcitabine (Leukemia, 2003, Bresters, Broekhuizen). Here, a systematic study of drug combinations with Aplidin, for possible use in hematological malignancies

ORGANISM(S): Homo sapiens

SUBMITTER: Rita Humeniuk 

PROVIDER: E-GEOD-5681 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress